



SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

INTERIM FINANCIAL STATEMENTS FOR THE 2ND HALF YEAR ENDED 31 DECEMBER 2023

CHARACTERISTICS OF THE LEAP MARKET OF BURSA MALAYSIA SECURITIES BERHAD (“BURSA SECURITIES”)

THE LEAP MARKET HAS BEEN POSITIONED AS A MARKET DESIGNED TO ACCOMMODATE CORPORATIONS TO WHICH A HIGHER INVESTMENT RISK MAY BE ATTACHED THAN OTHER CORPORATIONS LISTED ON THE ACE MARKET OR MAIN MARKET OF BURSA SECURITIES. IT IS A QUALIFIED MARKET WHICH IS MEANT MAINLY FOR SOPHISTICATED INVESTORS ONLY. ONLY EXISTING SECURITIES HOLDERS AND SOPHISTICATED INVESTORS ARE ALLOWED TO PARTICIPATE IN CORPORATE EXERCISES UNDERTAKEN BY SUPERGENICS BERHAD (“SGBHD” OR THE “COMPANY”). SOPHISTICATED INVESTORS SHOULD BE AWARE OF THE POTENTIAL RISKS OF INVESTING IN SUCH CORPORATIONS AND SHOULD MAKE THE DECISION TO INVEST ONLY AFTER DUE AND CAREFUL CONSIDERATION.

SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2ND HALF YEAR ENDED 31 DECEMBER 2023

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	INDIVIDUAL 6 Months Ended		CUMULATIVE Year To Date	
	31 Dec 2023 RM'000	31 Dec 2022 RM'000	31 Dec 2023 RM'000	31 Dec 2022 RM'000
Revenue	5,299	5,686	9,788	10,716
Cost of sales	(2,897)	(3,404)	(5,676)	(6,936)
Gross profit	2,402	2,282	4,112	3,780
Other operating income	712	98	1,074	190
Operating and administrative expenses	(1,983)	(1,475)	(3,688)	(2,815)
Net allowance for expected credit loss	(75)	36	(75)	36
Profit/(Loss) from operations	1,056	941	1,423	1,191
Finance costs	(213)	(175)	(420)	(357)
Share of associate's results	(148)	(63)	(148)	(63)
Profit/(Loss) before taxation	695	703	855	771
Taxation	(568)	(411)	(682)	(425)
Total comprehensive profit/(Loss)	127	292	173	346
Total comprehensive profit/(Loss) attributable to :				
Owners of the parent	155	292	201	346
Non-controlling interests	(28)	-	(28)	-
	127	292	173	346
Earning/(Loss) per-share	sen	sen	sen	sen
Basic	0.16	0.31	0.21	0.37
Diluted	N/A	N/A	N/A	N/A

The Condensed Consolidated Statement of Profit or Loss and Other Comprehensive income should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2022.

SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2ND HALF YEAR ENDED 31 DECEMBER 2023**CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

	(UNAUDITED) As At 31 Dec 2023 RM'000	(AUDITED) As At 31 Dec 2022 RM'000
ASSETS		
NON-CURRENT ASSETS		
Property, plant and equipment	4,988	4,180
Right-of-use assets	950	1,366
Investment in associate	31	179
Intangible asset	174	60
Contract assets	137	310
Deferred tax assets	32	32
	6,312	6,127
CURRENT ASSETS		
Inventories	-	10
Work in progress	408	-
Trade receivables	8,219	7,643
Other receivables	1,260	442
Other financial assets	83	58
Contract assets	173	141
Contract costs	-	701
Tax recoverable	-	86
Cash and bank balances	2,405	280
	12,548	9,361
TOTAL ASSETS	18,860	15,488
EQUITY		
Share capital	9,777	6,302
Merger reserve	(1,450)	(1,450)
Foreign currency reserve	1	-
Retained earnings	392	190
	8,720	5,042
Non-controlling Interests	(26)	-
Total Equity	8,694	5,042
LIABILITIES		
NON-CURRENT LIABILITIES		
Lease liabilities	1,398	1,104
Bank borrowings	2,347	2,801
	3,745	3,905
CURRENT LIABILITIES		
Trade payables	1,601	3,447
Other payables	3,240	766
Contract liabilities	227	1,037
Amount owing to directors	5	-
Lease liabilities	316	367
Bank borrowings	771	882
Provision for taxation	261	42
	6,421	6,541
TOTAL LIABILITIES	10,166	10,446
TOTAL EQUITY AND LIABILITIES	18,860	15,488
NET ASSETS PER-SHARE (RM)	0.092	0.054

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2022.

SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2ND HALF YEAR ENDED 31 DECEMBER 2023**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**

GROUP	← ATTRIBUTABLE TO THE OWNERS OF THE PARENT →				TOTAL RM'000	Non- controlling Interests RM'000	TOTAL EQUITY RM'000
	Non-distributable		Distributable				
	Share Capital RM'000	Merger Reserve RM'000	Foreign Exchange Reserve RM'000	Retained Earnings/ RM'000			
As at 1 Jan 2023	6,302	(1,450)	-	190	5,042	-	5,042
Profit for the financial period, representing total comprehensive income for the financial period	-	-	-	47	47	-	47
As at 30 Jun 2023	6,302	(1,450)	-	237	5,089	-	5,089
Profit for the financial year, representing total comprehensive income for the financial year	-	-	-	155	155	(28)	127
Other comprehensive income	-	-	1	-	1	-	1
Transactions with owners:-							
Issuance of ordinary shares	3,500	-	-	-	3,500	-	3,500
Share issuance expenses	(25)	-	-	-	(25)	-	(25)
Effects arising from changes in composition of the Group	-	-	-	-	-	2	2
Total transactions with owners	3,475	-	-	-	3,475	2	3,477
As at 31 Dec 2023	9,777	(1,450)	1	392	8,720	(26)	8,694
As at 1 Jan 2022	6,302	(1,450)	-	(156)	4,696	-	4,696
Profit for the financial year, representing total comprehensive income for the financial year	-	-	-	346	346	-	346
As at 31 Dec 2022	6,302	(1,450)	-	190	5,042	-	5,042

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2022.

SUPERGENICS BERHAD

(Company No. 201601043153 (1214095-X))

(Incorporated in Malaysia)

UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2ND HALF YEAR ENDED 31 DECEMBER 2023**CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS**

	12 Months Ended 31 Dec 2023 (UNAUDITED) RM'000	12 Months Ended 31 Dec 2022 (AUDITED) RM'000
CASH FLOW FROM OPERATING ACTIVITIES		
Profit before taxation	855	771
Adjustments for:		
Depreciation of property, plant and equipment	704	571
Depreciation of right-of-use asset	232	303
Gain on disposal of property, plant and equipment	-	(49)
Impairment loss on trade receivables	75	(36)
Reversal of impairment loss on trade receivables	(208)	-
Amortisation of intangible assets	6	-
Share of associate's results	148	63
Interest expenses	420	357
Interest income	(27)	-
Fair value gain on financial assets at fair value through profit and loss	(37)	(2)
Operating profit before working capital changes	2,168	1,978
Changes in working capital:		
Increase in inventories	10	(10)
Work in progress	(408)	-
Trade & other receivables	(1,262)	(2,668)
Trade & other payables	673	688
Amount owing from associate	-	-
Contract assets & liabilities	(668)	369
Contract costs	701	(187)
Amount owing to directors	(40)	-
	(994)	(1,808)
Cash generated from operations	1,174	170
Interest received	27	-
Tax paid	(377)	(190)
	(350)	(190)
Net cash generated from/(used in) operating activities	824	(20)
CASH FLOW FROM INVESTING ACTIVITIES		
(Additional)/Withdrawal in other investment	12	21
Addition in intangible asset	(120)	(60)
Purchase of property, plant and equipment	(1,328)	(358)
Proceed from disposal of property, plant and equipment	-	49
Deposit received from disposal of plant and equipment	-	200
Investment in an associate	-	(242)
Net cash used in investing activities	(1,436)	(390)
CASH FLOW FROM FINANCING ACTIVITIES		
Interest paid	(420)	(357)
Drawdown of borrowings	1,863	570
Repayment of borrowings	(2,154)	(1,663)
Proceed/(Repayment) of lease liabilities	243	(320)
Proceeds from issuance of share capital, net of share issuance expenses	3,476	-
Subscription of shares from non-controlling interests in subsidiaries	2	-
Net cash generated from/(used in) financing activities	3,010	(1,770)
Net increase/(decrease) in cash and cash equivalents	2,398	(2,180)
Cash and cash equivalents at beginning of the year	6	2,186
Currency translation differences	1	-
Cash and cash equivalents at end of the year	2,405	6
CASH AND CASH EQUIVALENTS AT END OF THE YEAR COMPRISES:		
Cash and bank balances	2,405	280
Less: Bank overdraft	-	(274)
	2,405	6

The Condensed Consolidated Statement of Cash Flows should be read in conjunction with the Audited Financial Statements for the year ended 31 Dec 2022.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2nd HALF YEAR ENDED
31 DEC 2023**

**PART A: EXPLANATORY NOTES IN COMPLIANCE WITH MALAYSIAN FINANCIAL
REPORTING STANDARD (“MFRS”) 134: INTERIM FINANCIAL REPORTING**

A1) Basis of preparation

This interim financial statements have been prepared under the historical cost convention. This interim financial statements are unaudited and have been prepared in accordance with the requirements of Malaysian Financial Reporting Standards (“MFRS”) 134: Interim Financial Reporting and as well as Rule 6.12 and Appendix 6A of the LEAP Market Listing Requirements of Bursa Malaysia Securities Berhad (“Bursa Securities”).

The interim financial report should be read in conjunction with the Audited Financial Statements for the financial year ended 31 Dec 2022 and the accompanying explanatory notes attached to this interim financial report.

A2) Significant accounting policies and application of MFRS

The accounting policies adopted are consistent with those of the previous financial year except the amendments to following accounting standards that are effective for the Group's financial year beginning on or after 1 Jan 2023:-

Description	Effective for annual periods beginning on or after
MFRS 17: Insurance Contracts Amendments to MFRS 17: Insurance Contracts	1 Jan 2023
Amendments to MFRS 112: Deferred tax related to Assets and Liabilities arising from a single transaction	1 Jan 2023
Amendments to MFRS 112: Pillar Two Model Rules	1 Jan 2023
Amendments to MFRS 101: Disclosure of Accounting Policies	1 Jan 2023
Amendments to MFRS 108: Definition of Accounting Estimates	1 Jan 2023



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2nd HALF YEAR ENDED
31 DEC 2023**

A2) Significant accounting policies and application of MFRS (Cont'd)

The above amendments to accounting standards effective during the financial year do not have any significant impact on the interim financial report of the Group.

As at the date of authorisation of this Condensed Report, the following accounting Standards and amendments to accounting Standards have been issued by the Malaysian Accounting Standards Board ("MASB") but are not yet effective:-

Description	Effective for annual periods beginning on or after
Amendments to MFRS 16: Lease Liability in a Sale and Leaseback	1 Jan 2024
Amendments to MFRS 101: Non-current Liabilities with Covenants	1 Jan 2024
Amendments to MFRS 107 and MFRS 7: Supplier Financing Arrangements	1 Jan 2024

Effective date of these Amendments to Standards has been deferred, and yet to be announced:-

Amendments to MFRS 10 Consolidated Financial Statements and MFRS 128 Investments in Associates and Joint Venture – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture.

The above pronouncements are either not relevant or do not have any impact on the financial statements of the Group.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2nd HALF YEAR ENDED
31 DEC 2023**

A3) Seasonal or cyclical factors

The Group's performance is not significantly affected by seasonal and cyclical factors.

A4) Unusual items

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the reporting period under review.

A5) Material changes in estimates

There were no significant changes in the nature and amount of estimates reported in the prior interim period of the current financial period or prior years that have a material effect on the current financial period ended 31 Dec 2023 under review.

A6) Debt and equity securities

Saved as disclosed below, there were no issuance or repayment of debt and equity securities, share buy-backs, share cancellations, share held as treasury shares by the Group during the financial period:-

- (a) 14,705,883 new ordinary shares were issued pursuant to the first tranche of the Private Placement, approved by shareholders at an extraordinary general meeting on 7 Nov 2023, at an issue price of RM0.238 per share which was listed on 24 Nov 2023.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2nd HALF YEAR ENDED
31 DEC 2023**

A7) Segmental reporting

The Group's segmental report for the current financial period ended 31 Dec 2023 under review are as follows:-

Revenue by Business Activities

	Individual 6 Months Ended		Cumulative Year To Date	
	31 Dec 2023 RM'000	31 Dec 2022 RM'000	31 Dec 2023 RM'000	31 Dec 2022 RM'000
REVENUE				
Provision of integrated turnkey solutions	1,813	4,014	3,964	8,159
Provision of maintenance services	19	572	544	1,051
Laboratory Services	3,467	1,100	5,280	1,506
Total consolidated revenue	5,299	5,686	9,788	10,716

A8) Valuation of property, plant and equipment

There was no valuation on any of the Group's property, plant & equipment during the reporting period ended 31 Dec 2023.

A9) Significant events

There were no events of a material nature to be disclosed in the interim financial statements for the current financial period ended 31 Dec 2023.

A10) Material changes in the composition of the Group

During the reporting period, the following subsidiaries were incorporated:-

- 1) On 21 Jul 2023 and 29 Aug 2023, the Company had incorporated two new wholly owned subsidiaries namely, Supergenics Global Sdn Bhd and Supergenics Bio Agro Sdn Bhd with respective issued share capital of RM100.
- 2) On 28 Sep 2023, a new subsidiary was incorporated in Hong Kong with issued share capital of HKD10,000, with 70% shareholding held by the Company's subsidiary, Supergenics Global Sdn Bhd.
- 3) The Company had incorporated another new subsidiary, Supergenics Stembank Sdn Bhd on 20 Nov 2023, with shareholding of 80%.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2nd HALF YEAR ENDED
31 DEC 2023**

A11) Contingent liabilities and contingent assets

There were no material contingent liabilities or assets for the reporting period ended 31 Dec 2023.

A12) Material events subsequent to the end of the interim financial report

The management is not aware of any material events subsequent to the end of the interim financial report that have not been reflected in the financial statements for the current financial report ended 31 Dec 2023 under review, save and except for the followings:-

We refer to the announcement dated 4 Aug 2023, 4 Sep 2023, 17 Oct 2023, 15 Nov 2023, 23 Nov 2023, 24 Nov 2023 and Circular to shareholders dated 23 Oct 2023 in relation to the Private Placement.

The Board had on 19 Jan 2024 fixed the issue price for the 2nd tranche of the Private Placement comprising 4,201,688 Placement Shares at RM0.238 per share which was completed and listed on the LEAP Market of Bursa Securities on 2 Feb 2024.

Subsequently on 14 Feb 2024, the Board had fixed the issue price for 3rd tranche of the Private Placement comprising 3,781,510 Placement Shares at RM0.238 per share which was completed and listed on the LEAP Market on 23 Feb 2024.

A13) Capital commitment

There was no commitment for the purchase of property, plant and equipment provided for in the current financial report ended 31 Dec 2023.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2nd HALF YEAR ENDED
31 DEC 2023**

**PART B: ADDITIONAL INFORMATION REQUIRED UNDER THE LEAP MARKET LISTING
REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD**

B1) Review of performance

(i) 2nd Half Year, FY 2023 (“H2FY2023”) vs 2nd Half Year, FY 2022 (“H2FY2022”)

	INDIVIDUAL			CUMULATIVE		
	6 Months Ended		Variance	Year To Date		Variance
	31 Dec 2023	31 Dec 2022		31 Dec 2023	31 Dec 2022	
	RM'000	RM'000	%	RM'000	RM'000	%
Revenue	5,299	5,686	(6.8)	9,788	10,716	(8.7)
Gross profit	2,402	2,282	5.3	4,112	3,780	8.8
Profit/(Loss) before taxation	695	703	(1.1)	855	771	10.9

For the current financial period under review, the Group posted a revenue of RM5.30 mil as compared to its corresponding preceding financial period, H2FY2022 of RM5.69 mil. The increase in the revenue from laboratory services which driven by the growth in regenerative treatment segment has mitigate the impact from the reduced revenue in the project-based income and maintenance services, which were due to lesser number of projects awarded for the reporting period.

The Group had improved its performance by increasing the profit before taxation for the year, the Group has recorded profit before taxation of RM0.86 mil as compared to its last financial year profit before taxation of RM0.77 mil which was mainly contributed by the growth in revenue from laboratory services with higher profit margin.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2nd HALF YEAR ENDED
31 DEC 2023**

B1) Review of performance (Cont'd)

(ii) Changes in revenue and PBT for H2FY2023 as compared with the immediate preceding period ended 30 Jun 2023 (“H1FY2023”)

	Current	Immediate	
	6 Months Ended		Variance
	31 Dec 2023	30 Jun 2023	
	RM'000	RM'000	%
Revenue	5,299	4,490	18.0
Gross profit	2,402	1,710	40.5
Profit/(Loss) before taxation	695	161	331.8

The Group has recorded revenue of RM5.30 mil with profit before taxation of RM0.70 mil for the 2nd half year ended 31 Dec 2023 as compared to the immediate preceding half year which recorded revenue of RM4.49 mil and profit before taxation of RM0.16 mil. The increase in profit before taxation mainly contributed by the higher revenue in the laboratory services with higher profit margin.

B2) Future prospects

The Malaysian economy expanded by 3% in the fourth quarter of 2023 (3Q 2023: 3.3%; 2Q 2023: 2.9%). Household spending remained supported by improving labour market conditions and easing cost pressures. The unemployment rate declined to the pre-pandemic level of 3.3% while the labour force participation rate was at a historic high in 2023. Meanwhile, growth in investment activity was underpinned by the progressive realisation of multi-year projects and capacity expansion by firms. Exports, however, remained subdued due to prolonged weakness in external demand amid stronger imports. On the supply side, there was a broad-based expansion. The commodities sector grew. This was supported by higher oil and gas production as well as expansion in the agriculture sector amid improved labour supply. The services and construction sectors continued to expand. The manufacturing sector remained soft from continued weakness in the electrical and electronics industry. In terms of monthly GDP, December recorded a growth of 1.4%, lower than November (3.8%) and October (3.9%), attributed mainly to the shorter school holiday period during the month and weaker export-oriented manufacturing sector. On a quarter-on-quarter seasonally-adjusted basis, the economy contracted by 2.1% (3Q 2023: +2.6%).



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2nd HALF YEAR ENDED
31 DEC 2023**

B2) Future prospects (Cont'd)

Overall, the 2023 growth for the Malaysian economy normalised to 3.7%, following a strong growth registered in the previous year (2022: 8.7%). Growth moderated amid a challenging external environment. This was due mainly to slower global trade, the global tech downcycle, geopolitical tensions and tighter monetary policies. On the domestic front, despite the lapse of large policy support provided as the economy started to open up in 2022, the continued recovery in economic activity and labour market conditions supported growth in 2023. In addition, the solid growth performance of the economy is reinforced by a resilient external position. Despite the challenging external environment, the current account surplus for the year 2023 was sustained at 1.2% of GDP, supported by a diversified export structure across market and product. The strength in external position is also reflected in the external debt, which declined to 68.2% of GDP in 2023 (3Q 2023: 69%), and a higher net international investment position at 6.6% of GDP in 2023 (3Q 2023: 5.2%). Importantly, the external debt remains manageable given the favourable maturity and currency profiles. One-third of the external debt is denominated in ringgit, limiting currency risk, while around 70% of debt have medium and longer-term tenures. Foreign currency borrowings are also subject to Bank Negara Malaysia (BNM)'s prudential requirements and continue to consist mainly of concessionary intragroup loans.

Headline inflation continued to decline to 1.6% during the quarter (3Q 2023: 2%). The downward trend was contributed by the moderation in fresh food inflation (4Q 2023: 0.5%; 3Q 2023: 1.9%) and core inflation (2%; 3Q 2023: 2.5%). The lower core inflation was largely driven by an easing in services sub-segments, including food away from home and repair and maintenance of personal transport. Inflation pervasiveness continued to trend lower, as the share of Consumer Price Index items recording monthly price increases moderated to 36.3% during the quarter (3Q 2023: 40.8%). This brought inflation pervasiveness below its fourth quarter long-term average (2011-2019) of 41.7%. For 2023 as a whole, headline inflation declined to 2.5% (2022: 3.3%) while core inflation averaged at 3% (2022: 3%).

Growth in 2024 will be driven by resilient domestic expenditure and improvement in external demand. On the external front, the IMF is projecting a rebound in global trade growth from 0.4% in 2023 to 3.3% in 2024. Together with the tech upcycle, the stronger external demand and continued improvement in the tourism sector will provide support to Malaysia's exports. On the domestic front, household spending will be supported by continued employment and wage growth. Investment activity will be underpinned by further progress of multi-year projects, by both the private and public sectors, as well as the implementation of catalytic initiatives under the



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2nd HALF YEAR ENDED
31 DEC 2023**

B2) Future prospects (Cont'd)

various national master plans. Improvement in tourist arrivals and spending are expected to continue.

The growth outlook remains subject to downside risks stemming from weaker-than-expected external demand and larger declines in commodity production. Nonetheless, there are upside risks to growth emanating from greater spillover from the tech upcycle, stronger-than-expected tourism activity and faster implementation of existing and new projects.

(Source: Economic and Financial Developments in Malaysia in the Fourth Quarter of 2023, Bank Negara Malaysia)

The Group is strategically expanding its presence throughout Southeast Asia, with a specific focus on emerging markets such as Indonesia, Vietnam, China, and the Philippines. Leveraging its expertise in upstream bioprocess design and training, the Group is dedicated to facilitating the establishment of state-of-the-art biomanufacturing facilities for potential clients. Upon completion of these facilities, meticulously designed and proposed by the Group, clients will gain access to a diverse array of downstream cell-based products tailored to address various biotechnological needs.

With an unwavering commitment to innovation and client-centric solutions, the Group's roadmap includes the development of comprehensive biomanufacturing ecosystems covering both upstream processes and downstream product offerings, alongside essential supportive infrastructure. Through this integrated approach, the Group aims to position itself as a pivotal partner in propelling the advancement of biotechnology industries across the region.

Moreover, the Group is vigorously seeking avenues to advance its proprietary technologies, exemplified by the Supergenics' Laboratory Monitoring and Control System. This innovative system is tailored to address the distinct requirements of biomanufacturing facilities. Additionally, the Group has developed the Supergenics Modular Panel (SGMP), a cutting-edge cleanroom wall and furniture panel crafted from premium materials such as stainless steel, aluminum, or powder-coated mild steel. By equipping clients with state-of-the-art tools to regulate and optimize their operations, the Group strives not only to meet but to exceed industry benchmarks for efficiency, quality, and regulatory compliance.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2nd HALF YEAR ENDED
31 DEC 2023**

B2) Future prospects (Cont'd)

As the demand for biopharmaceuticals and other biotechnology products continues to escalate in Southeast Asia, the Group foresees a surge in interest for its comprehensive solutions. With a proven track record and forward-thinking strategies, the Group is well-positioned to capitalize on these opportunities and drive growth across new markets, all while delivering value to clients and stakeholders.

Moreover, in tandem with its traditional business operations, the Group's expansion into the Regenerative Treatment Segment is poised to significantly bolster its future prospects. Having successfully generated revenue from this segment since the fiscal year ending (FYE) 2021, the Group observed a remarkable doubling of revenue by FYE 2022. This growth underscores the segment's potential as a lucrative avenue for the Group's revenue streams.

Looking forward, the Group aims to further fortify its Regenerative Treatment Segment through strategic partnerships with service providers in the health, wellness, or aesthetic industries. By leveraging these partnerships, the Group seeks to amplify product sales within this segment, penetrate new markets, and diversify its revenue streams.

The management of Supergenics holds an optimistic view of the Regenerative Treatment Segment's outlook, recognizing it as a rapidly growing sector with substantial potential to propel the Group's future growth trajectory. With a steadfast commitment to innovation and a keen eye on emerging trends in the healthcare industry, the Group is poised to harness the opportunities presented by this dynamic market segment, thereby delivering sustained value to its stakeholders.

B3) Profit forecast, Profit Guarantee and Internal Targets

The group has not issued any profit forecast, profit guarantee in any form of public documentation and announcement.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2nd HALF YEAR ENDED
31 DEC 2023**

PART C: OTHER INFORMATION

C1) Status of Corporate Proposal

Save as disclosed below, there were no other corporate proposals announced but pending completion as at the date of this report:-

- i) The Company had on 4 Aug 2023 announced the private placement of up to 26,000,000 new ordinary shares in the Company, representing approximately 27.96% of the existing total number of issued shares of the Company at an issue price to be determined and announced later ("Private Placement") and the diversification of the principal activities of the Company and its subsidiaries to include the provision of administrative health care services, operating of medical laboratories and development of regenerative treatment products for medical treatment and wellness ("Diversification"). Shareholders' approval for the Private Placement and Diversification were obtained at the extraordinary general meeting held on 7 Nov 2023.

The Board had on 15 Nov 2023 fixed the issue price for the 1st tranche of the Private Placement comprising 14,705,883 Placement Shares at RM0.238 per share which was listed on the LEAP Market of Bursa Securities on 24 Nov 2023.

The Board had on 19 Jan 2024 fixed the issue price for the 2nd tranche of the Private Placement comprising 4,201,688 Placement Shares at RM0.238 per share which was listed subsequently on 2 Feb 2024.

Subsequently on 14 Feb 2024, the Board had fixed the issue price for 3rd tranche of the Private Placement comprising 3,781,510 Placement Shares at RM0.238 per share which was completed and listed on 23 Feb 2024.

C2) Material Litigation

The management is not aware of any pending material litigation which will have a material effect on the financial position or the business of the Group and the Board is not aware of any proceedings pending or threatened against the Group or of any fact likely to give rise to any proceedings which may materially and adversely affect the financial position or business of the Group at the date of this report.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2nd HALF YEAR ENDED
31 DEC 2023**

C3) Dividends

No dividend has been declared by the Group since the end of the previous financial year. The Board of Directors do not recommend any dividend in respect of the current financial period under review.

C4) Utilisation of Proceeds

The proposed utilization of proceeds from the fund raising of RM 6.0 mil are as follows:-

Description	Proposed Utilisation RM'000	Actual Utilisation RM'000	Balance RM'000	Timeframe for Utilisation Upon Listing
(I) Manufacturing of the SGMP	2,000	-	2,000	12 months
(II) R&D of technology used in the production of regenerative treatment products	2,000	(240)	1,760	12 months
(III) Repayment of bank borrowings	1,200	(1,194)	6	6 months
(IV) Working capital	706	(705)	1	6 months
(V) Estimated expenses	100	(95)	5	Immediate
	6,006	(2,234)	3,772	

Note:-

(1) As at the date of this report, the actual gross proceeds raised from the Private Placement were RM5.4 Mil

(2) The actual utilisation is up to the date of this report.



**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE 2nd HALF YEAR ENDED
 31 DEC 2023**

C5) Earnings per share

	Individual 6 Months Ended		Cumulative Year To Date	
	31 Dec 2023	31 Dec 2022	31 Dec 2023	31 Dec 2022
a) Basic earnings per-share				
Profit attributable to the owners of parent ('000)	155	292	201	346
Total weighted average number of ordinary shares in issue ('000)	94,289	93,000	94,289	93,000
Basic earning per share (sen)	0.16	0.31	0.21	0.37
b) Diluted earnings per-share	N/A	N/A	N/A	N/A

C6) Authorisation for issue

The interim financial report were authorised for issue by the Board of Directors in accordance with resolution of the directors on 29 Feb 2024.